Two studies demonstrated SYMBICORT's effectiveness in improving health-related quality of life (HRQL) and patient-reported satisfaction with asthma treatment. The combination therapy showed significant improvements in HRQL scores compared to monocomponents or placebo, while also demonstrating better patient-reported global assessments.
A new study found that patients with healed erosive esophagitis had better acid control and lower heartburn symptom scores compared to those who did not heal. The study suggests that controlling gastric acid levels is key to healing erosive esophagitis.
A 12-month study showed that NEXIUM maintained normal acid production levels in most patients with Zollinger-Ellison syndrome. Most participants controlled their acid output after just 10 days, and no ulcers or erosive esophagitis were observed at the end of the year.
Pooled data from clinical trials showed significantly fewer patients taking Nexium developed an ulcer compared to those on placebo. The study demonstrated reduced stomach ulcer risk in patients at high risk for complications associated with NSAID use.
AstraZeneca scientists have discovered selective and potent inhibitors of Aurora kinase activity that may have potential application in human cancer treatment. New pre-clinical research presents a combination of vascular targeting agents with EGFR tyrosine kinase inhibitors, showing greater anti-tumor activity than either agent alone.
The STELLAR study found CRESTOR 10-40mg reduced LDL-C by 46 to 55 percent, while raising HDL-C by 7.6 to 9.6 percent compared to other statins. The study was part of AstraZeneca's GALAXY Program and included over 19,000 patients from 23 countries.